title: Profile of gantenerumab and its potential in the treatment of Alzheimer's disease.
abstract: Alzheimer's disease, which is characterized by gradual cognitive decline associated with deterioration of daily living activities and behavioral disturbances throughout the course of the disease, is estimated to affect 27 million people around the world. It is expected that the illness will affect about 63 million people by 2030, and 114 million by 2050, worldwide. Current Alzheimer's disease medications may ease symptoms for a time but are not capable of slowing down disease progression. Indeed, all currently available therapies, such as cholinesterase inhibitors (donepezil, galantamine, rivastigmine), are primarily considered symptomatic therapies, although recent data also suggest possible disease-modifying effects. Gantenerumab is an investigational fully human anti-amyloid beta monoclonal antibody with a high capacity to bind and remove beta-amyloid plaques in the brain. This compound, currently undergoing Phase II and III clinical trials represents a promising agent with a disease-modifying potential in Alzheimer's disease. Here, we present an overview of gantenerumab ranging from preclinical studies to human clinical trials.
authors.affiliation: Department of Physiology and Pharmacology, Sapienza University of Rome, Rome, Italy.
authors.forename: Dijana
authors.initials: D
authors.lastname: Novakovic
authors.forename: Marco
authors.initials: M
authors.lastname: Feligioni
authors.forename: Sergio
authors.initials: S
authors.lastname: Scaccianoce
authors.forename: Alessandra
authors.initials: A
authors.lastname: Caruso
authors.forename: Sonia
authors.initials: S
authors.lastname: Piccinin
authors.forename: Chiara
authors.initials: C
authors.lastname: Schepisi
authors.forename: Francesco
authors.initials: F
authors.lastname: Errico
authors.forename: Nicola B
authors.initials: NB
authors.lastname: Mercuri
authors.forename: Ferdinando
authors.initials: F
authors.lastname: Nicoletti
authors.forename: Robert
authors.initials: R
authors.lastname: Nisticò
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy* / Q000503:physiopathology; D016229:Amyloid beta-Peptides / Q000037:antagonists & inhibitors*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001921:Brain / Q000187:drug effects / Q000503:physiopathology; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D004353:Drug Evaluation, Preclinical; D006801:Humans
chemical_list: D016229:Amyloid beta-Peptides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C571128:gantenerumab
keywords: Alzheimer’s disease; amyloid-β; clinical trials; gantenerumab; monoclonal antibody